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Abstract
 
BCAP was recently cloned as a binding molecule to phosphoinositide 3-kinase (PI3K). To
investigate the role of BCAP, mutant mice deficient in BCAP were generated. While
BCAP-deficient mice are viable, they have decreased numbers of mature B cells and B1 B
cell deficiency. The mice produce lower titers of serum immunoglobulin (Ig)M and IgG3,
and mount attenuated responses to T cell–independent type II antigen. Upon B cell receptor
 
cross-linking, BCAP-deficient B cells exhibit reduced Ca
 
2
 
 
 
 mobilization and poor prolifera-
tive responses. These findings demonstrate that BCAP plays a pivotal immunoregulatory role
in B cell development and humoral immune responses.
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Introduction
 
B cell development proceeds through sequential stages
characterized by stage-specific surface marker expression
(1–4). The B lineage cells in the bone marrow first initiate
rearrangement of IgH locus and incorporate the resulting
 
protein into the pre-B cell receptor (pre-BCR),
 
*
 
 the ex-
pression of which is the hallmark of the development of
pro-B cells into pre-B cells. Then, the rearrangement of
IgL locus occurs and the BCR is subsequently assembled,
marking the progression of pre-B cells to immature B cells.
 
Immature B220
 
 
 
 B cells highly expressing IgM exit from
the bone marrow and immigrate into the spleen. Once in
 
the spleen, immature B cells, identified as IgM
 
hi
 
IgD
 
lo
 
 pop-
ulation, become IgM
 
hi
 
IgD
 
hi
 
 cells, which in turn develop
into IgM
 
lo
 
IgD
 
hi
 
 mature B cells (5). These developmental
progressions likely require the signaling ability of the pre-
BCR and BCR complex, as exemplified by the block be-
fore the pre-B cell stage in mice lacking the tyrosine kinase
Syk (6, 7).
The BCR utilizes sequential activation of three distinct
families of nonreceptor protein tyrosine kinases (PTKs),
such as Src, Syk, and Tec family, as initial activation (8).
Indeed, deficiencies in any of these three families of PTKs
result in defective or aberrant B cell function and develop-
ment (8–11). Thus, characterization of the substrates of
these activated PTKs is a prerequisite for understanding the
mechanism of how such initial activation regulates the bio-
logical outcomes of B cell function and development.
The phosphorylation events that these PTKs catalyze
both modulate the catalytic activity of effector enzymes and
mediate protein–protein interactions that juxtapose critical
signal transduction elements. In this context, it is increas-
ingly appreciated that a group of cellular proteins called
adaptor proteins regulate the interactions of effector en-
zymes with the BCR and their targets, thereby amplifying
and integrating multiple signaling pathways (12–14). In
support of this, the importance of adaptor proteins in nor-
mal B lymphocyte development has emerged. For exam-
ple, mutant mice lacking the adaptor protein B cell linker
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protein (BLNK; alternatively named SLP-65 or BASH)
manifest defective maturation of pro-B to pre-B cells as
well as impaired responses to T cell–independent (TI) anti-
gens (15–18).
BCAP has recently been isolated as an adaptor molecule
that binds to the p85 subunit of phosphoinositide 3-kinase
(PI3K; reference 19). It contains several characteristic struc-
tures, including an ankyrin repeat, coiled-coil regions, and
proline-rich stretches, in addition to several candidate tyro-
sine phosphorylation sites that could mediate interactions
with PI3K, Grb2, and Src homology 2 domain tyrosine
phosphatase 2 (SHP-2). Experiments with BCAP-deficient
DT40 B cells demonstrated that BCAP regulates BCR-
mediated phospholipase C (PLC)-
 
 
 
2 activation as well as
PI3K activation (19).
In an effort to understand the role of BCAP in B cell
development and function, we have generated mice defi-
cient in BCAP. Here, we find that BCAP is required for B
cell activation and maturation, and suggest that it causes
these biological consequences, at least in part, by regulat-
ing Ca
 
2
 
 
 
 flux.
 
Materials and Methods
 
Construction of BCAP Targeting Vector.
 
Partial 
 
BCAP
 
 genome
in pBleoBAC11 vector was obtained from Genome Systems. A
targeting vector was designed to replace a 2.4-kbp genomic frag-
ment with neomycin resistance gene (
 
neo
 
) from pMC1-neo-
poly(A) (Stratagene), deleting the BCAP exon harboring three
YxxM motifs. A herpes simplex virus-thymidine kinase cassette
(
 
TK
 
) mediating negative selection was inserted in the 5
 
 
 
 end of
the BCAP-neo construct.
 
Generation of BCAP
 
 
 
/
 
 
 
 Mice.
 
The SalI-linealized BCAP tar-
geting construct was electroporated into E14.1 embryonic stem
(ES) cells and the selection of ES cells was performed with G418
and gancyclovir as described previously (20). 550 ES cell colonies
were screened by PCR. Nine PCR-positive ES clones were ob-
tained, all of which gave the expected bands by Southern blot
analysis. Six independent clones were injected into blastocysts and
three of them gave rise to chimeric mice that transmitted the mu-
tation to the germline. The mice were maintained under specific
pathogen-free conditions. Genotyping of mice was performed by
Southern blot analysis.
 
Northern Blot Analysis.
 
RNA was extracted from spleens us-
ing RNAzol B (Tel-Test Inc.). 20 
 
 
 
g of total RNA was sepa-
rated on a 1% agarose formaldehyde gel, transferred to Hybond-
N
 
 
 
 membrane (Amersham Pharmacia Biotech), and probed with
 
32
 
P-labeled mouse BCAP full-length cDNA or 
 
 
 
-actin.
 
Flow Cytometric Analysis.
 
The expression of surface antigens
was determined by standard flow cytometric methods. Single-
cell suspensions from the indicated organs were depleted of
erythrocytes by osmotic lysis and aliquots of 10
 
6
 
 cells were
stained with a combination of FITC-, PE-, and CyChrome-con-
jugated antibodies. The following mAbs used in the flow cyto-
metric analyses were purchased from BD PharMingen: anti-CD4
(GK1.5), anti-CD5 (53–7.3), anti-CD8 (53–6.72), anti-CD11b
(M1/70), anti-CD16 (2.4G2), anti-CD21 (7G6), anti-CD23
(B3B4), anti-CD43 (S7), anti-B220 (RA3–6B2), anti-heat stable
antigen (HSA; M1/69), and anti-IgM (R6–60.2), and anti-IgD
(11–26) was obtained from Southern Biotechnology Associates,
Inc. Data were collected on a FACScan™ flow cytometer (Bec-
 
ton Dickinson) and analyzed using CELLQuest™ software (Bec-
ton Dickinson).
 
Intracellular Staining Assays.
 
Single-cell suspensions from the
spleen were stained with a combination of PE- and CyChrome-
conjugated antibodies, washed, and fixed in PBS containing 3.7%
paraformaldehyde. Subsequently, cells were washed and perme-
abilized in PBS containing 0.1% Triton X-100. After blocking
with PBS with 10% fetal calf serum (staining buffer), cells were
stained with an antiserum to BCAP (diluted at 1:1,000 in staining
buffer) for 30 min at 4
 
 
 
C. Cells were washed and then stained
with goat anti–rabbit IgG (Jackson ImmunoResearch Laborato-
ries) at 0.2 
 
 
 
g/ml for 30 min at 4
 
 
 
C. Cells were washed and re-
suspended in ice-cold PBS for FACS
 
®
 
 analysis.
 
ELISA and Immunizations.
 
Total serum levels of IgM, IgG1,
IgG2a, IgG2b, IgG3, and IgA were determined using ELISA
quantitation kits (Bethyl Lab.). Bound Ig was detected using
TMB microwell peroxidase substrate system (Kirkegaard & Perry
Lab.). Concentrations were calculated from curves constructed
using mouse Ig standards ELISA quantitation kits contain. To
evaluate TI-II responses, wild-type and BCAP
 
 
 
/
 
 
 
 mice (five per
group) were immunized intraperitoneally with 20 
 
 
 
g of the thy-
mus-independent antigen TNP-Ficoll (Biosearch Technologies)
in PBS. Mice were bled before and 7 d after immunization. To
determine responses to a thymus-dependent antigen, wild-type
and BCAP
 
 
 
/
 
 
 
 mice (four per group) were immunized intraperi-
toneally with 20 
 
 
 
g TNP-KLH (Biosearch Technologies) in a 1:1
homogenate with complete Freund’s adjuvant (Difco). Mice
were bled before and 14 and 21 d after immunization. At day 14,
a second immunization (boost) with 20 
 
 
 
g TNP-KLH was per-
formed. Serum Abs specific for TNP were measured in Immuron
 
®
 
plates (Dynex) coated with TNP-BSA (Biosearch Technologies)
using ELISA quantitation kits (Bethyl). Immunoabsorbance was
read at 450 nm and titers were calculated relative to control sera
from unimmunized mice.
 
Proliferative Response of Splenic B Cells.
 
The spleen cell sus-
pensions were depleted of erythrocytes by osmotic lysis, and their
B cells were purified with Dynabead (Dynal) in combination
with antibodies against CD4, CD8, CD11b, and Gr-1 (all from
BD PharMingen). The resulting preparations (hereafter referred
to as splenic B cells) contained 93 and 90% B220
 
 
 
 cells from
wild-type and BCAP
 
 
 
/
 
 
 
 mice, respectively. Splenic B cells were
cultured, either directly or immediately after sorting with a
FACS Vantage™ (Becton Dickinson) using anti-B220 and anti-
HSA antibodies, in 0.2 ml of RPMI 1640 (GIBCO BRL) con-
taining 10% fetal calf serum, 50 
 
 
 
M 2-mercaptoethanol, 2 mM
L-glutamine, penicillin, and streptomycin at a density of 1.5 
 
 
 
10
 
5
 
 cells/well in flat-bottom 96-well plates. The cells were stim-
ulated with 15 
 
 
 
g/ml F(ab
 
 
 
)
 
2
 
 goat anti-IgM Ab (Jackson Immu-
noResearch Laboratories), 10 
 
 
 
g/ml rat agonistic anti-CD40
mAb (clone 3/23; Serotec), or 10 
 
 
 
g/ml LPS (Sigma-Aldrich).
For the last 8 h of the 48-h culture period the cultures were
pulsed with 0.5 
 
 
 
Ci/well [
 
3
 
H]thymidine. They were then har-
vested onto glass-fiber filters, and radioactivity was measured us-
ing a 
 
 
 
 counter.
 
Ca
 
2
 
 
 
 Measurement.
 
Continuous monitoring of fluorescence
from the total splenic B cells was performed using Fura-2/AM
(Molecular Probes) as an indicator as described previously (21).
Ca
 
2
 
 
 
 mobilization in the subpopulations of splenic B cells was
separately measured using a BD LSR (Becton Dickinson) as fol-
lows: erythrocyte-depleted splenocytes were loaded with 1.2
 
 
 
M Indo-1AM (Sigma-Aldrich) and then incubated with anti-
HSA-FITC and anti-B220-PE antibodies. Cells were washed
and stimulated with 15 
 
 
 
g/ml F(ab
 
 
 
)
 
2
 
 goat anti-IgM Ab. In- 
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creases in intracellular Ca
 
2
 
 
 
 were recorded in real time on live-
gated cells.
 
Immunoprecipitation and Western Blot Analysis.
 
Immunopre-
cipitation (IP) and Western blotting were performed as described
previously using the following antibodies: anti-phosphotyrosine
(Upstate Biotechnology), anti-Syk (Santa Cruz Biotechnology,
Inc.), anti-Btk (43–3B) provided by S. Arai (Hayashibara Bio-
chemical Lab., Okayama, Japan) and S. Tsukada (Osaka Univer-
sity, Osaka, Japan), anti-PLC-
 
 
 
2 (Santa Cruz Biotechnology,
Inc.), and antisera to BCAP and BLNK, which we raised against
GST-BCAP and GST-BLNK, respectively. To determine the ki-
nase activity of Akt, in vitro kinase assays were done as described
previously using histone (H2B) as a substrate (19).
 
Inositol-1,4,5-trisphosphate Generation.
 
Inositol-1,4,5-trisphos-
phate (IP
 
3
 
) generation in BCR-stimulated splenic B cells was
measured with IP
 
3
 
 [
 
3
 
H] assay system (Amersham Pharmacia Bio-
tech) according to manufacturer’s instructions.
 
In Vitro PI3K Assay.
 
Splenic B cells were stimulated with 15
 
 
 
g/ml F(ab
 
 
 
)
 
2
 
 goat anti-IgM Ab and were lysed in ice-cold lysis
buffer (137 mM NaCl, 20 mM Tris-Cl, pH 8.0, 1% NP-40, 10%
glycerol, 1 mM Na
 
3
 
VO
 
4
 
, 1 
 
 
 
g/ml leupeptin, 0.1 
 
 
 
g/ml aproti-
nin, and 1 mM phenylmethlsulfonyl fluoride). After insoluble
materials were removed by centrifugation, the supernatants were
incubated with antisera recognizing PI3K p85 subunit (Upstate
Biotechnology). Immunoprecipitates were recovered with pro-
tein A sepharose, washed sequentially with lysis buffer, wash
buffer A (0.1 M Tris-Cl, pH 7.4, 5 mM LiCl, and 0.5 mM
Na
 
3
 
VO
 
4
 
) and wash buffer B (10 mM Tris-Cl, pH 7.4, 100 mM
NaCl, 1 mM EDTA, and 0.5 mM Na
 
3
 
VO
 
4
 
), and were finally re-
suspended in 20 mM HEPES (pH 7.4). Kinase reactions were
started by addition of 10 
 
 
 
Ci [
 
 
 
-
 
32
 
P]ATP, 15 
 
 
 
g of phosphati-
dylinositol (Sigma-Aldrich), MgCl
 
2
 
 (15 mM final), and ATP (40
 
 
 
M final). Reactions were terminated with 1 M HCl after incu-
bation at 37
 
 
 
C for 10 min. After organic extraction, aqueous
samples were spotted onto TLC plates and phosphorylated prod-
ucts were separated in a CHCl
 
3
 
/methanol/4 M NH
 
4
 
OH (9:7:2)
developing solvent. The incorporated radioactivity was measured
using a Fuji FLA2000 bioimaging analyzer (Fuji Photo Film).
 
Results
 
Generation of BCAP
 
 
 
/
 
 
 
 Mice.
 
We constructed a gene-
targeting vector such that homologous recombination
would replace an exon and its flanking introns with a neo-
mycin resistance gene (
 
neo
 
), deleting three YxxM motifs
that mediate binding to the p85 subunit of PI3K (Fig. 1
A). Nine ES clones with the appropriately targeted allele
were obtained. Six clones were injected into C57BL/6
blastocysts and three of those yielded chimeric mice that
transmitted the mutations to their offsprings. Southern
blot analysis using an external probe confirmed the pres-
ence of the targeted locus (Fig. 1 B). Founder mice show-
ing germline transmission were interbred to produce
homozygous BCAP
 
 
 
/
 
 
 
 mice, which were born at the ex-
pected Mendelian ratio. BCAP
 
 
 
/
 
 
 
 mice appeared healthy
and were fertile.
The expression of BCAP in the mutant mice was exam-
ined both at the RNA and protein levels. Northern blot
analysis using the BCAP full-length cDNA as a probe re-
vealed no messenger RNA in the homozygous mice (Fig. 1
C). We previously showed that mouse splenic B cells ex-
press two major BCAP isoforms (100- and 98-kD long iso-
Figure 1. Generation of BCAP /  mice. (A) Schematic representation
of the strategy used to target the BCAP locus. Exons are presented as
shaded boxes and numbered, where the exon containing the initiation
methionine corresponds to exon 1. Exon 8 (E8) harboring three YxxM
motifs was replaced with the neomycin selection cassette (neo). Neo and
thymidine kinase (tk) are shown as open arrows that indicate the direction
of transcription. A probe used for Southern blot analysis is also shown as a
bar. EV; EcoRV. (B) Representative Southern blot analysis of genomic
DNA of progeny mice. Tail DNA was digested with EcoRV and probed
with the external probe shown in panel A.  / ,  / , and  /  indi-
cate wild-type, heterozygous, and homozygous mice, respectively. (C)
Northern blot analysis of total RNA from the spleen. A blot was hybrid-
ized with either BCAP full-length cDNA or  -actin. (D) Western blot
analysis of BCAP protein from splenocytes. Immunoprecipitates from
lysates with antiserum to BCAP or anti-BLNK antibody were immuno-
blotted with the same antibodies.538 Contribution of BCAP to B Cell Development and Humoral Responses
forms and 72- and 70-kD short isoforms) presumably by al-
ternative initiation or splicing (19). Western blot analysis of
splenic B cells with an antiserum to BCAP (19) displayed
no expression of either BCAP isoform in the mutant mice
in accord with Northern blot data (Fig. 1 D).
Defective B Cell Development in BCAP /  Mice. BCAP
expression, as determined by intracellular flow cytometric
staining, was detected in B220  B cells, but not in CD3 
T cells (Fig. 2 A). Cellularity in the thymus of BCAP / 
mice was equivalent to that in wild-type mice, and thy-
mocyte development was normal, as assessed by expression
of CD4 and CD8 (Table I and Fig. 2 B). Then, B cell de-
velopment in BCAP /  mice was examined by multipa-
rameter flow cytometry. In the bone marrow of BCAP / 
mice, no gross developmental arrest was found except for a
reduction of pre-B cell subset compared with wild-type
mice (Table I and Fig. 2 B). The number of B220  cells in
the bone marrow did not differ significantly between
wild-type and the mutant mice. In the spleen, the total
number of cells was reduced by 20–30% in the mutant
mice. Reflecting this decrease, the number of B220  cells
in the spleen of BCAP /  mice was reduced by 20–30%
relative to that in wild-type littermate controls (Table I).
Moreover, transition from IgMhiIgDhi cells to IgMloIgDhi
mature B cells was considerably blocked, resulting in the
lowered ratio of IgMloIgDhi to IgMhiIgDhi cells in the
spleen of BCAP /  mice compared with that of wild-type
mice (0.75   0.20 versus 2.25   0.20; Fig. 2 B). The
percentages of marginal zone (MZ) B cells (CD21hi
CD23loB220 ), which are thought to contribute to TI im-
mune responses (22, 23), were comparable in the spleens
between BCAP /  and wild-type mice. In contrast, a
slight decrease of follicular B cells (CD21intCD23hiB220 )
was observed in BCAP /  mice, presumably reflecting a
Figure 2. Flow cytometric
analysis of lymphocyte popula-
tions in BCAP / mice. (A) Ex-
pression of BCAP in splenic B
cells. Spleen cells stained for
CD3 and B220 were analyzed by
flow cytometric intracellular
staining with an antiserum to
BCAP plus goat anti–rabbit
IgG-FITC (thick solid line,
wild-type mice; shaded area,
BCAP /  mice). Data shown are
representative of three indepen-
dent experiments. (B) Single-cell
suspensions from thymus (Thy),
bone marrow (BM), lymph node
(LN), spleen (SP), and peritoneal
cavity (PerC), were stained with
the indicated Abs and analyzed
using a FACScan® (wt, wild-type
mice). Numbers indicate the
percentages of lymphoid cells in
the quadrants or enclosed areas.
IgM versus IgD and CD21 ver-
sus CD23 profiles are shown for
B220  cells, and CD11b versus
CD16 profile for B220  cells.
Data shown are representative of
six independent experiments.539 Yamazaki et al.
blocked development beyond the immature B cell stage
(Fig. 2 B). As in the spleen, the lymph nodes of BCAP / 
mice also had a reduced subpopulation of mature IgMloIg-
Dhi B cells. In addition, CD5-expressing B1 B cells, usu-
ally found in larger amounts in the peritoneal cavity, were
virtually absent in BCAP /  mice (Fig. 2 B). Hence, we
conclude that BCAP is indispensable for the production of
B1 B cells, but not for MZ B cells, and contributes to the
development of conventional B cells, particularly to the
transition from immature to mature B cells.
BCAP transcript was detected in macrophage cell lines as
well as B cell lines (19). We thus determined whether the
lack of BCAP affected macrophage development. Al-
though the number of CD11b CD16 B220  cells con-
taining the macrophage lineage was marginally decreased in
the spleens of BCAP /  mice relative to wild-type litter-
mate controls, no difference in the proportion of this subset
was found between these mice (Table I and Fig. 2 B). Sim-
ilarly, the number of CD3  T cells in the spleen from
BCAP /  mice was marginally decreased (Table I).
Attenuated Humoral Immune Responses in BCAP / 
Mice. To further assess the consequences of BCAP defi-
ciency, we first measured Ig production in unimmunized
mice. Decreased titers of both IgM and IgG3 were seen in
BCAP /  mice (Fig. 3 A), corresponding to a lack of
CD5-expressing B1 B cells in their peritoneal cavities. A
slight reduction in IgG2b was also seen. In contrast, serum
concentrations of IgG1, IgG2a, and IgA were not different
from those in littermate controls.
Then, to determine whether BCAP /  mice can re-
spond to TI and T cell–dependent (TD) antigens, we im-
munized mice intraperitoneally with TI type II (TI-II,
TNP-Ficoll) and TD (TNP-KLH) antigens. 7 d after im-
munization with TNP-Ficoll, we measured serum titers
of the hapten-specific immunoglobulins by ELISA.
BCAP /  mice produced TNP-specific immunoglobulins
of any of the isotypes to a lesser extent than wild-type
mice (Fig. 3 B).
14 d after immunization with TNP-KLH, TNP-specific
immunoglobulin titers were measured. TNP-specific IgG1,
IgG2a, and IgG2b were yielded in BCAP /  mice equiva-
lently to wild-type mice, although the production of both
IgM and IgG3 was reduced (Fig. 3 C). Reimmunization of
wild-type mice with TNP-KLH 14 d after primary immu-
nization induced a robust secondary TD response. Simi-
larly, BCAP /  mice upon this boosting mounted a re-
markable secondary response to TD antigens, nonetheless,
with reduced titers of both IgM and IgG3. Therefore,
BCAP /  mice are able to respond to TD antigens, in con-
trast to their attenuated TI-II responses.
Impaired BCR Signaling in BCAP /  Splenic B Cells.
The basis of humoral response is the ability of individual B
cells to respond to an array of antigens, which is tightly reg-
ulated by signals through the BCR complex (24, 25). Thus,
we directly assessed the growth response of BCAP /  B
cells to various stimulations in vitro. As shown in Fig. 4 A,
BCAP /  B cells did respond poorly to antigen receptor
stimulation with F(ab )2 anti-IgM Ab compared with wild-
type B cells. Interestingly, the ability of BCAP /  B cells to
respond to either CD40 ligation or LPS stimulation was re-
duced to almost 50% of that of wild-type B cells. Given
that mature B cells proliferate upon BCR engagement
whereas immature B cells are particularly susceptible to
BCR-triggered apoptosis (26, 27), the reduced thymidine
uptake observed in BCAP /  B cells might reflect the low-
ered ratio of mature/immature B cells in the spleen of mu-
tant mice (Fig. 2 B). We thus used HSA as a maturation
marker to separate splenic B cells into B220 HSAhi imma-
ture B and B220 HSAlo mature B cells (28, 29). As shown
in Fig. 4 B, both fractions of splenic B cells from the mu-
tant mice responded poorly to BCR triggering.
To further evaluate the defects of BCR signals in
BCAP /  B cells, we measured the mobilization of in-
tracellular calcium, as Ca2  flux is implicated in both B cell
maturation and BCR-induced B cell proliferation (21, 30).
BCR-elicited Ca2  flux in BCAP /  B cells was reduced
in amplitude compared with that in wild-type B cells (Fig.
5 A). This overall change cannot be ascribed to develop-
mental differences between wild-type and BCAP /  mice;
both immature and mature subsets of BCAP /  B cells ex-
hibited attenuated Ca2  flux (Fig. 5 B). As IP3 is a critical
mediator for BCR-induced calcium mobilization, the re-
duced Ca2  flux in BCAP /  B cells could be explained, at
least partly, by impaired activation of PLC- 2. To test this
possibility, we directly measured IP3 generation upon
Table I. Lymphocyte Populations in BCAP /  Mice
Wild-type
(n   6)
BCAP / 
(n   6)
Bone marrow
Total cells 34.6   8.5 31.3   7.4
Total B cells 8.1   2.9 6.3   1.5
Pro-B cells (fractions A–C) 1.1   0.4 1.4   0.6
Pre-B cells (fraction D) 3.3   0.8 1.6   0.9
Immature B cells (fraction E) 2.6   1.7 2.6   1.4
Recirculating mature B cells
(fraction F)
1.1   0.5 0.7   0.2
Spleen
Total cells 66.5   21.8 48.6   19.8
B cells 38.6   8.0 27.0   12.2
T cells 16.6   3.1 12.4   8.6
Macrophages 11.5   5.0 9.0   7.5
Thymus
Total cells 295.3   232.1 262.5   93.5
Bone marrow cells were obtained from two femurs of mice 6–8 wk of
age. Cell populations were determined on the basis of the total cell count
and flow cytometric analysis shown in Fig. 2 B. Data are means  
standard deviation and represent multiples of 106 cells. Subsets in the
bone marrow are defined as follow: pro-B, B220 CD43 IgM ; pre-B,
B220 CD43 IgM ; immature B, B220loIgM ; mature B, B220hiIgM .540 Contribution of BCAP to B Cell Development and Humoral Responses
BCR stimulation. Indeed, BCAP /  B cells yielded 20–30%
less IP3 than wild-type controls (Fig. 5 C). Accordingly,
we conclude that PLC- 2 is not sufficiently activated in
the absence of BCAP, thereby leading to insufficient cal-
cium flux.
To examine the molecular mechanism underlying the
insufficient PLC- 2 activation in BCAP /  B cells, we first
compared the BCR-mediated tyrosine phosphorylation
status of PLC- 2 in mutant versus wild-type B cells. PLC-
 2 was normally tyrosine phosphorylated in BCAP /  B
cells after BCR ligation, as was seen in wild-type B cells
(Fig. 6 A). Consistent with this observation, the BCR-
mediated tyrosine phosphorylation status of BLNK, Syk,
and Btk, molecules responsible for PLC- 2 phosphoryla-
tion (31), did not significantly differ between BCAP / 
and wild-type B cells (Fig. 6 A).
Not only upstream PTKs but PI3K is implicated in
PLC- 2 activation. Phosphatidylinositol-3,4,5-trisphosphate
(PIP3) generated by PI3K is thought to mediate membrane
targeting of both Btk and PLC- 2 via its interactions with
PH domains, thereby participating in PLC- 2 activation
(32–34). Thus, it is possible that BCAP indirectly facilitates
PLC- 2 activation by activating PI3K. To address this pos-
sibility, we directly measured PI3K activity. BCAP /  B
cells exhibited PI3K activation similarly to wild-type B cells
(Fig. 6 B). In support of this, Akt activity was not signifi-
cantly affected by the loss of BCAP (Fig. 6 C). As a control,
treatment with the PI3K inhibitor LY294002 reduced the
Akt kinase activity to the basal levels in both BCAP /  and
wild-type B cells. Taken together, BCAP is likely involved
in PLC- 2 activation independently of tyrosine phosphory-
lation and PI3K activation.
Discussion
We show here that a lack of BCAP, which is a substrate
of BCR-activated PTKs, leads to defects in B cell develop-
ment and humoral immune responses. Although the BCAP
protein has been detected in macrophage cell lines (data
not shown), BCAP is unlikely to play an essential role in
macrophage development in that macrophage numbers are
only slightly decreased in spleens of BCAP-deficient mice.
Moreover, overall T cell development appears normal in
BCAP /  mice, which is consistent with no detectable ex-
pression of BCAP in CD3  T cells (Fig. 2, A and B).
Elimination of BCAP does not result in the severe early
B cell developmental arrest. Rather, BCAP /  mice mani-
fest mainly defects in peripheral B cell populations. Splenic
Figure 3. Serum immunoglob-
ulin titers and the humoral re-
sponses in BCAP /  mice. (A)
The concentrations of serum Ig
isotypes measured by ELISA.
The values for each individual
wild-type ( ) and BCAP / 
( ) mouse tested are plotted.
Bars indicate mean values. (B)
Attenuated TI-II responses in
BCAP /  mice. Group of five
wild-type ( ) and BCAP / 
( ) mice were immunized with
the TI-II antigen TNP-Ficoll.
Mice were bled before (d 0) and
7 d (d 7) after immunization.
TNP-specific immunoglobulins
of the indicated isotypes were
expressed in relative units com-
pared with a standard titrated se-
rum. Representative data of two
independent experiments are
shown. (C) Group of four wild-
type ( ) and BCAP /  (  )
mice were immunized with the
TD antigen TNP-KLH. Mice
were reimmunized with the
same antigen at day 14, and were
bled before (d 0) immunization
and at day 14 (d 14) and 21 (d
21). Relative amounts of TNP-
specific immunoglobulins were
analyzed as described in B. Rep-
resentative data of two indepen-
dent experiments are shown.541 Yamazaki et al.
B cells are present, albeit somewhat reduced in number,
and are skewed toward an immature phenotype, with an
over-representation of IgMhiIgDlo cells and a decrease of
IgMloIgDhi fraction (Fig. 2 B). Immature B cells that emi-
grate from the bone marrow to the periphery are referred
to as transitional B cells. Only 10–30% of transitional B
cells enter the long-lived mature peripheral B cell compart-
ment (27, 35, 36). This entering mechanism is not entirely
clear, but BCR signaling appears to be an important deter-
minant in this transition. Indeed, loss of BCR expression
by conditional IgM ablation aborts all further development
from the transitional to mature B cell stage (37). Hence, the
developmental arrest at the immature B cell stage in
BCAP /  mice could be explained by two mechanisms; (a)
the BCAP mutation affects BCR signaling, thereby inter-
fering with differentiation to mature B cells; (b) although
this maturation occurs in BCAP /  mice, albeit at low lev-
els, the survival of mature B cells requires BCAP.
B1 cells often express germline-encoded self-reactive
BCRs and favoring the B1 cell development could be a
function of BCR signaling and positive selection (38). MZ
B cells may be selected similarly to the B1 population, as
there are shared characteristics between B1 and MZ B cells
(39). For example, B cells harboring a bias for self-reactive
BCRs are also enriched in the MZ subset (40). BCAP / 
mice display a lack of CD5-expressing B1 B cells (found
primarily in the peritoneal cavity), while MZ B cell popu-
lation, defined as CD21hiCD23lo B cells, appears normal
(Fig. 2 B). Assuming that BCAP functions as a positive reg-
ulator in BCR signaling, the straightforward explanation of
these data is that the decreased BCR signaling by loss of
BCAP is still sufficient to promote the maturation and/or
survival of the MZ subset, but not the B1 subset. These re-
sults nevertheless allow for the alternative possibility that
qualitative differences in BCR signaling determine MZ or
B1 cell fate.
TI-II antigens, which are typically derived from
polysaccharides, usually consist of complex repeating units
that drive B cell responses by extensive cross-linking of
specific BCRs. Both B1 and MZ B cells are thought to be
responsible for a TI-II response (41). Thus, an impaired
TI-II response in BCAP /  mice could be simply ex-
plained by the lack of CD5-expressing B1 B cells. How-
ever, considering the importance of MZ B cells in the TI-
II response (22, 23), dysfunction of MZ B cells in BCAP / 
mice, in addition to B1 deficiency, could contribute to the
impaired TI-II response. In this regard, we would like to
speculate that despite the dispensability of BCAP for MZ
B cell development, BCAP could be required for MZ B
cells to transduce extensive BCR engagement and thereby
generate TI-II responses. In contrast to an impaired re-
sponse to TI-II antigens, BCAP /  mice mounted a robust
response to a TD antigen (Fig. 3 C). These data, together
with normal germinal center formation observed in
BCAP /  mice (data not shown), suggest that BCAP is
not normally involved in the formation and activation of
memory B cells.
The phenotype of BCAP /  mice resembles that of
mice lacking Btk (xid) (42, 43). Both mutant mice manifest
reduced levels of mature B cells; an increase in transitional
B cells; CD5  B1 cell deficiency; low serum IgM and IgG3
levels; defective humoral responses to TI-II antigens; poor
proliferative responses after stimulation via the BCR, anti-
CD40, and LPS; and reduced Ca2  responses upon BCR
engagement. A number of signaling molecules whose dis-
ruption causes a phenotype similar to xid have now been
identified, including BLNK (15–18), Vav1/Vav2 (44, 45),
PLC- 2 (21, 30), and PI3K p85  (46, 47). A common
property of all these molecules including BCAP is their
regulation of calcium flux.
Figure 4. Impaired proliferative response of BCAP /  splenic B cells.
(A) Purified splenic B cells from wild-type and BCAP /  mice were cul-
tured with medium, F(ab )2 goat anti-IgM Ab (15  g/ml), rat anti-CD40
Ab (10  g/ml), or LPS (10  g/ml). The mean and standard deviations are
plotted for wild-type (black bars) and BCAP /  splenic B cells (white
bars). Experiments were performed in triplicates. Data shown are repre-
sentative of three independent experiments. (B) Splenic B cells from the
indicated mice were sorted into B220 HSAhi (immature B) and
B220 HSAlo (mature B) subsets, and experiments were performed in trip-
licates. Data shown are representative of three independent experiments.542 Contribution of BCAP to B Cell Development and Humoral Responses
Given the importance of PI3K in calcium flux, we ex-
pected that the reduced Ca2  response in BCAP /  B cells
was attributable to an impairment of BCR-mediated PI3K
activation, because we previously showed that BCR-medi-
ated PI3K activation was partly blocked by loss of BCAP in
chicken DT40 B cells (19). However, elimination of
mouse BCAP does not significantly interfere with PI3K ac-
tivity upon BCR cross-linking (Fig. 6, B and C). This ap-
parent discrepancy might simply reflect differences be-
tween transformed and primary B cells. A recent study has
provided the possibility that PI3K pathway is not nega-
tively regulated under a normal fashion in transformed
lymphocytes. Indeed, the Jurkat T cell line is shown to be
devoid of PTEN, a negative regulator of PI3K signaling
(48). Thus, if so in DT40 B cells, the PI3K pathway in this
transformed cell line might not reflect the normal regula-
tory manner in naive B cells. Alternatively, this disparity
might reflect species differences between chicken and
mouse. In this regard, there exist at least two possibilities.
First, mouse B cells might utilize other PI3K binding pro-
teins, such as CD19 (49, 50) and Gab1 (51), rather than
BCAP, to activate PI3K pathway upon BCR engagement.
Second, chickens have only one isoform of BCAP, whereas
mice might have several BCAP isoforms that could func-
tion redundantly in BCR-mediated PI3K activation.
Therefore, apparently normal PI3K activation in mouse
BCAP /  B cells raises the question of how BCAP is in-
volved in PLC- 2/calcium pathway. Calcium signals are
triggered by the second messenger IP3, the product of the
hydrolyzing action of PLC- 2 on phosphatidylinositol-
4,5-bisphosphate (PIP2). The attenuated IP3 generation in
BCAP /  B cells could be accounted for by the decreased
availability of the PLC- 2 substrate PIP2 and/or by the de-
creased hydrolysis of PIP2 through insufficient PLC- 2 ac-
tivation. In this context, if the former mechanism is domi-
nantly operating, we predicted that BCR-mediated PI3K
activation was similarly attenuated, as PI3K utilizes the
same substrate, PIP2, to generate PIP3. Thus, normal Akt
activation in BCAP /  B cells could place the latter possi-
bility more likely.
BCAP appears to participate in PLC- 2 activation
through phosphorylation-independent mechanisms, be-
cause of the normal tyrosine phosphorylation status of
PLC- 2 in BCAP /  B cells. Thus, at least two possibili-
ties might account for the manner by which BCAP regu-
lates PLC- 2 activation. First, as PLC- 2 should be tar-
geted to subdomains of the plasma membrane known as
rafts for its activation (52), BCAP might contribute to this
recruitment. Given that BLNK is required for PLC- 2 tar-
geting (53), BCAP could act in concert with BLNK,
Figure 5. Defective Ca2  mobilization in BCAP /  splenic B cells. (A)
Splenic B cells were loaded with Fura-2/AM. Cell were washed, stimu-
lated with F(ab )2 goat anti-IgM Ab (15  g/ml), and then with ionomy-
cin (1  M). Fluorescence from the cell suspension was continuously
monitored using a Hitachi F-2000 fluorescence spectrophotometer. In
three other experiments, peak values of [Ca2 ]i in BCAP /  B cells were
55, 63, and 66% of those in wild-type B cells, respectively. Data shown
are representative of four independent experiments. (B) Erythrocyte-
depleted splenocytes were loaded with Indo-1AM. Fluorescence from
each subpopulation was collected on a BD LSR. Ca2  concentrations are
represented as the ratio of bound to unbound Indo-1. Data shown are
representative of three independent experiments. (C) Reduced IP3 gener-
ation in BCAP /  splenic B cells. Splenic B cells were stimulated with
F(ab )2 goat anti-IgM Ab (15  g/ml), and lyzed. IP3 generation from 107
cells at each time point was measured ( , wild-type;  , BCAP / ). In
three other experiments, amounts of IP3 in BCAP /  B cells (after 30 s of
anti-IgM stimulation) were reduced by 20, 27, and 30%, respectively,
compared with those in wild-type B cells. Data shown are representative
of four independent experiments.543 Yamazaki et al.
thereby ensuring sufficient targeting of PLC- 2. Second,
considering the requirement for conformational changes of
PLC- 2 (54), in addition to its targeting, in its full activa-
tion, BCAP might be involved in forming the active con-
formation of PLC- 2. Indeed, a recent report has demon-
strated that binding of PLC- 1 to multiple adaptors,
including linker for activation of T cells (LAT), Gads, and
SLP-76, is required for its optimal activation (55, 56). Al-
though it is clear that the insufficient PLC- 2 activation in
BCAP /  B cells contributes to the decreased calcium
flux, this mechanism may not entirely account for the ef-
fect of BCAP on calcium mobilization. For example,
BCAP could directly regulate a calcium influx channel on
the plasma membrane. Hence, it might be reasonable to
anticipate that BCAP is an important molecule for forming
a spatially compact signaling complex including PLC- 2
and calcium channels on the plasma membrane (“the sig-
nalosome”) (57, 58).
The data presented here support the concept that quanti-
tative differences in intracellular Ca2  can have clear effects
on subsequent activation of downstream signaling events,
which in turn affect B cell development. Extracellular sig-
nal–regulated kinase (ERK), c-Jun NH2-terminal kinase
(JNK), p38 cascades, and the Ca2 -dependent transcription
factors nuclear factor of activated T cells (NFAT) and NF-
 B could be potential targets of calcium signaling (59–61).
In addition, given the importance of calcium concentration
for Rag2 expression and apoptosis in immature B cells (62),
BCAP might contribute to B cell tolerance by modulating
receptor editing and/or cell deletion.
Figure 6. Tyrosine phosphorylation in BCAP / 
splenic B cells. (A) BCR-elicited tyrosine phosphorylation
status of PLC- 2, BLNK, Syk, and Btk. Splenic B cells
(2   107 cells for each time point) were stimulated with
F(ab )2 goat anti-IgM Ab (15  g/ml), lyzed, and immuno-
precipitated with the indicated antibodies. Immune com-
plexes were resolved by SDS-PAGE and sequentially
immunoblotted with anti-phosphotyrosine and the
immunoprecipitating antibody. Data shown are represen-
tative of three independent experiments. (B) BCR-medi-
ated PI3K activation. The results present the fold activa-
tion as a stimulation index between resting and activated
cells. The mean and standard deviations of three indepen-
dent experiments are plotted for wild-type (black bars) and
BCAP /  splenic B cells (white bars). (C) BCR-induced
activation of Akt. Either with or without 15 min incuba-
tion with 10  M LY294002, splenic B cells were stimu-
lated with F(ab )2 goat anti-IgM Ab (15  g/ml), lyzed, and
immunoprecipitated with anti-Akt 1 Ab. Half of Akt im-
munoprecipitates was assayed for in vitro kinase activity
using H2B as a substrate. The reactions were separated by
SDS-PAGE and autoradiogrammed (top panel). The pro-
tein levels of Akt were analyzed using the remaining half of
Akt immunoprecipitates (bottom panel). Data shown are
representative of three independent experiments.544 Contribution of BCAP to B Cell Development and Humoral Responses
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